Recent News

  1. Dear Valued RUBY-FILL User, Please find here an important drug safety communication, as requested by the FDA, regarding the potential risk to high-level radiation exposure in some patients due to Sr-82 and Sr-85 breakthrough in the eluate when using an incorrect solution to elute a Rubidium Rb-82 generator and failure (...)
  2. We are pleased to announce that we have partnered with other industry leaders on a joint industrial communication to the nuclear medicine community in an effort to raise awareness regarding the potential supply of non-FDA approved products to their institutions.    
  3. Jubilant DraxImage recently participated in the Family Health Campaign in which we joined industry advocates, leaders and professionals to raise awareness of the continuously growing impact of cardiovascular disease and the growing number of deaths associated with it – 1 in 4 deaths in the U.S. is caused by heart disease and (...)
  4. Legal action from Bracco Diagnostics, Inc. regarding patent infringement Montreal, QC, April 4, 2018 – Jubilant DraxImage Inc. (“DraxImage”), recently learned of legal challenges filed by Bracco Diagnostics, Inc. (“Bracco“) including a complaint filed with the U.S. International Trade Commission (ITC) regarding alleged patent infringement related to the Jubilant DraxImage (...)
  5. Jubilant DraxImage receives approval for new pulmonary indications from the U.S. Food and Drug Administration for DRAXIMAGE® DTPA Montreal, QC, December 27 2017 – Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma wholly-owned subsidiary, is pleased to announce approval of new pulmonary indications for DRAXIMAGE® DTPA (Kit for the Preparation of Technetium (...)
  6. 2nd Annual Miami Thyroid Oncology Symposium Thyroid Cancer Management in the Age of Genomics and Molecular Theranostics February 2-3, 2018 | Kovens Conference Center The 2nd Annual Miami Thyroid Oncology Symposium will highlight the changing paradigm in thyroid cancer management in the age of genomics and molecular diagnostic. Distinguished faculty (...)
  7. Jubilant DraxImage receives FDA approval for 12-Hour shelf-life for DRAXIMAGE® MAA Montreal, QC, October 26, 2017 – Jubilant DraxImage Inc. (“DraxImage”), a wholly-owned subsidiary of Jubilant Pharma, is pleased to announce the U.S. Food and Drug Administration (FDA) approval for the extension of the in-use shelf life of DRAXIMAGE® MAA (...)
  8. Jubilant DraxImage held an informative and interactive advisory panel  discussion on Cardiac PET with Rb-82 with moderator Dr. Gary Heller.  At the Jubilant DraxImage booth, various ASNC attendees were given demonstrations of the Rubidium Elution System.
  9. Jubilant Pharma Limited (“JPL”) a wholly owned subsidiary of Jubilant Life Sciences Ltd. through one of its subsidiaries announced today that it has signed an Agreement to acquire substantially all of the assets which comprise the radiopharmacy business of Triad Isotopes Inc. (“Triad”). See notification below.
  10. Michael Rossi is a significant addition with an impressive track record. Montreal, April 9, 2014 – Jubilant DraxIamge Inc., a Jubilant Life Sciences Company, is pleased to announce the appointment of Mr. Michael Rossi as Vice President, Sales and Business Operations, Jubilant DraxImage Inc., with effect from the 21st April 2014. (...)